Drug Profile
hMaxi-K gene therapy - Sumitomo Pharma America
Alternative Names: hMaxi-K - Ion Channel Innovations; hMaxi-K; pVAX/hSlo; URO 902Latest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Ion Channel Innovations LLC
- Developer Ion Channel Innovations
- Class Erectile dysfunction therapies; Gene therapies; Urologics
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction; Overactive bladder
Most Recent Events
- 15 May 2023 Discontinued - Phase-II for Erectile dysfunction in Kuwait (Intracavernous)
- 15 May 2023 Discontinued - Phase-II for Overactive bladder (Treatment-experienced) in USA (Intravesicular)
- 28 Apr 2023 Final efficacy and adverse events data from a phase IIa trial in Overactive bladder presented at the 118th Annual Meeting of the American Urological Association (AUA-2023)